Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL237 dose-finding study in rheumatoid arthritis
NCT04638426Phase 2Unknown
- Sponsor
- Hanlim Pharm
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HL237 in rheumatoid arthritis (RA) (4 arms), sponsored by Hanlim Pharm. Primary endpoint: American College of Rheumatology 20 response rate at 12 weeks. Status: unknown.
02
Drugs
HL237
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04638426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638426.